SRPT Finishes Enrolment in Late-Stage Study for Rare Muscular Disorder [Yahoo! Finance]
Sarepta Therapeutics, Inc. (SRPT)
Last sarepta therapeutics, inc. earnings: 2/26 04:05 pm
Check Earnings Report
US:NASDAQ Investor Relations:
investorrelations.sarepta.com/events-and-presentations
Company Research
Source: Yahoo! Finance
Sarepta Therapeutics has completed enrolment and dosing in the phase III EMERGENE study evaluating its investigational gene therapy, SRP-9003, for treating limb-girdle muscular dystrophy (LGMD) Type 2E/R4. Was this helpful? Yes No How has Sarepta Therapeutics' stock performed recently, and what is its current Zacks Rank? Year to date, Sarepta Therapeutics' shares have risen 24.7% against the industry's 10.5% decline. Sarepta Therapeutics currently carries a Zacks Rank #2 (Buy)..) Was this helpful? Yes No What are some other top-ranked biotech stocks, according to Zacks Investment Research? Some other top-ranked stocks from the sector are Castle Biosciences (CSTL) and CytomX Therapeutics (CTMX), each sporting a Zacks Rank #1 (Strong Buy) at present. at present.) Was this helpful? Yes No What is Sarepta Therapeutics' current commercial portfolio for Duchenne muscular dystrophy (DMD) treatments? Sarepta's commercial portfolio includes three approved RNA-bas
Show less
Read more
Impact Snapshot
Event Time:
SRPT
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
SRPT alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
SRPT alerts
High impacting Sarepta Therapeutics, Inc. news events
Weekly update
A roundup of the hottest topics
SRPT
News
- High Growth Tech Stocks To Watch For Potential Opportunities [Yahoo! Finance]Yahoo! Finance
- High Growth Tech Stocks To Watch In December 2024 [Yahoo! Finance]Yahoo! Finance
- High Growth Tech And 2 Other Promising Stocks With Strong Potential [Yahoo! Finance]Yahoo! Finance
- Sarepta Therapeutics, Inc. (NASDAQ: SRPT) had its "sell" rating re-affirmed by analysts at HC Wainwright. They now have a $75.00 price target on the stock.MarketBeat
- Sarepta Therapeutics Completes Enrollment in EMERGENE, a Phase 3 Clinical Study of SRP-9003 for the Treatment of Limb-Girdle Muscular Dystrophy Type 2E/R4 [Yahoo! Finance]Yahoo! Finance
SRPT
Earnings
- 11/6/24 - Beat
SRPT
Sec Filings
- 12/16/24 - Form 4
- 12/12/24 - Form 144
- 12/6/24 - Form 4
- SRPT's page on the SEC website